Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset - Lee, Ki Hyeong; Cho, Byoung Chul; Ahn, Myung-Ju; Lee, Yun-Gyoo; Lee, Youngjoo; Lee, Jong-Seok; Kim, Joo-Hang; Min, Young Joo; Lee, Gyeong-Won; Lee, Sung Sook; Lee, Kyung-Hee; Ko, Yoon Ho; et al. (Cancer Research and Treatment, 2024)
Keywords: Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; ErbB Receptors - genetics; ErbB Receptors - metabolism; Gefitinib - therapeutic use; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Morpholines; Mutation; Original; Original Article; Protein Kinase Inhibitors - adverse effects; Pyrazoles; Pyrimidines; Quinazolines; Republic of Korea; 의학일반; Republic of Korea; EGFR mutation; Lazertinib; Non-small-cell lung carcinoma